## **Amendments to the Claims**

Please amend the claims as follows:

Claims 1-14 (Cancelled)

Claim 15 (Currently Amended) A compound medicament according to any of Claims 1 to 12 formula (I)

$$R^{5}$$
 $R^{6}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{8}$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{6}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{9}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{3}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{5$ 

wherein:

n is 1, 2, 3 or 4;

## R<sup>1</sup> is selected from

- (a) an optionally substituted straight chain or branched chain C<sub>1-6</sub> alkyl group,
- (b) an optionally substituted straight chain or branched chain C<sub>2-6</sub> alkenyl group,
- (c) an optionally substituted straight chain or branched chain C<sub>2-6</sub> alkynyl group,
- (d) <u>Aryl</u>,
- (e) Aromatic heterocycle,
- (f) Heterocycle, and
- (g) <u>hydrogen;</u>

where the optional substituents in groups (a), (b) and (c) above are selected from: C<sub>3-7</sub> cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR<sup>9</sup>, NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>p</sub>R<sup>9</sup>, OC(O)R<sup>10</sup>, CO<sub>2</sub>R<sup>9</sup>, CONR<sup>9</sup>R<sup>10</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, halo and NHSO<sub>2</sub>R<sup>9</sup>, and where p is 0, 1 or 2;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each independently selected from hydrogen and

- straight chain or branched chain C<sub>1-6</sub> alkyl optionally substituted by OR<sup>9</sup> or halo;
- R<sup>9</sup> and R<sup>10</sup> are each independently selected from hydrogen and straight chain or branched chain C<sub>1-6</sub> alkyl;
- Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R<sup>11</sup>, halo, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>11</sup>, CO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>SO<sub>2</sub>R<sup>11</sup>, CN, haloalkyl, O(haloalkyl), SR<sup>12</sup>, S(O)R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, OC(O)R<sup>12</sup>, SO<sub>2</sub>NR<sup>12</sup>R<sup>13</sup> and C(O)NR<sup>12</sup>R<sup>13</sup>, where R<sup>11</sup> is straight chain or branched chain C<sub>1-6</sub> alkyl and R<sup>12</sup> and R<sup>13</sup> are each independently selected from hydrogen and straight chain or branched chain C<sub>1-6</sub> alkyl;
- Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, CO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>11</sup>, R<sup>11</sup>, halo, CN, haloalkyl, O(haloalkyl), SR<sup>12</sup>, S(O)R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, OC(O)R<sup>12</sup>, NR<sup>12</sup>SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>12</sup>R<sup>13</sup> and C(O)NR<sup>12</sup>R<sup>13</sup>; and
- Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, CO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>13</sup>, R<sup>11</sup>, halo, CN, haloalkyl, O(haloalkyl), SR<sup>12</sup>, S(O)R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, OC(O)R<sup>12</sup>, NR<sup>12</sup>SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>12</sup>R<sup>13</sup> and C(O)NR<sup>12</sup>R<sup>13</sup>,
- or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of said compound or said tautomer for use as a wherein said medicament is for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

Claim 16-21 (Cancelled)